Evidence map›Paper›PMID 39042472›Full record

ArticleJCI insight2024

EGR2 is an epigenomic regulator of phagocytosis and antifungal immunity in alveolar macrophages.

Zsuzsanna Kolostyak, Dora Bojcsuk, Viktoria Baksa, Zsuzsa Mathene Szigeti, Krisztian Bene, Zsolt Czimmerer, Pal Boto, Lina Fadel, Szilard Poliska, Laszlo Halasz and 14 more

Abstract read
In one paragraph

Article in JCI insight, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Zsuzsanna KolostyakDepartment of Biochemistry and Molecular Biology, Faculty of Medicine.
Dora BojcsukDepartment of Biochemistry and Molecular Biology, Faculty of Medicine.
Viktoria BaksaDepartment of Molecular Biotechnology and Microbiology, Faculty of Science, University of Debrecen, Debrecen, Hungary.
Zsuzsa Mathene SzigetiDepartment of Molecular Biotechnology and Microbiology, Faculty of Science, University of Debrecen, Debrecen, Hungary.
Krisztian BeneDepartment of Biochemistry and Molecular Biology, Faculty of Medicine.
Zsolt CzimmererDepartment of Biochemistry and Molecular Biology, Faculty of Medicine.
Pal BotoDepartment of Biochemistry and Molecular Biology, Faculty of Medicine.
Lina FadelDepartment of Biophysics and Cell Biology, and.
Szilard PoliskaGenomic Medicine and Bioinformatic Core Facility, Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Laszlo HalaszDepartments of Medicine and Biological Chemistry, Johns Hopkins University School of Medicine, Institute for Fundamental Biomedical Research, Johns Hopkins All Children's Hospital, St. Petersburg, Florida, USA.
Petros TzerposDepartment of Biochemistry and Molecular Biology, Faculty of Medicine.
Wilhelm K BergerDepartments of Medicine and Biological Chemistry, Johns Hopkins University School of Medicine, Institute for Fundamental Biomedical Research, Johns Hopkins All Children's Hospital, St. Petersburg, Florida, USA.
Andres Villabona-RuedaDivision of Pulmonary Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Zsofia VargaDepartment of Biochemistry and Molecular Biology, Faculty of Medicine.
Tunde KovacsDepartment of Medical Chemistry and.
Andreas PatsalosDepartments of Medicine and Biological Chemistry, Johns Hopkins University School of Medicine, Institute for Fundamental Biomedical Research, Johns Hopkins All Children's Hospital, St. Petersburg, Florida, USA.
Attila PapDepartment of Biochemistry and Molecular Biology, Faculty of Medicine.
Gyorgy VamosiDepartment of Biophysics and Cell Biology, and.
Peter BaiDepartment of Medical Chemistry and.
Balazs DezsoDepartment of Pathology, Faculty of Medicine, and.
Matthew SpiteCenter for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Franco R D'AlessioDivision of Pulmonary Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Istvan SzatmariGenomic Medicine and Bioinformatic Core Facility, Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Laszlo NagyDepartment of Biochemistry and Molecular Biology, Faculty of Medicine.

Funding

DHA-derived resolvin production andsignaling in tissue repair macrophages in metabolic diseaseR01DK124782 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI NAGY, LASZLO, SPITE, MATTHEW R · 2020 to 2023
$2.3M
Nuclear receptor, PPARg in macrophage polarization, hyperinflammatory gene expression and lung injuryR01HL170426 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI Laszlo Nagy · 2024 to 2026
$1.9M
PPARgamma as an architectural regulator of gene expression in endocrine signalingR01DK115924 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI NAGY, LASZLO · 2018 to 2021
$1.6M
NHLBI NIH HHS R01 HL170426NIDDK NIH HHS R01 DK115924NIDDK NIH HHS R01 DK124782
6 · The paper itself

Abstract

Alveolar macrophages (AMs) act as gatekeepers of the lung's immune responses, serving essential roles in recognizing and eliminating pathogens. The transcription factor (TF) early growth response 2 (EGR2) has been recently described as required for mature AMs in mice; however, its mechanisms of action have not been explored. Here, we identified EGR2 as an epigenomic regulator and likely direct proximal transcriptional activator in AMs using epigenomic approaches (RNA sequencing, ATAC sequencing, and CUT&RUN). The predicted direct proximal targets of EGR2 included a subset of AM identity genes and ones related to pathogen recognition, phagosome maturation, and adhesion, such as Clec7a, Atp6v0d2, Itgb2, Rhoc, and Tmsb10. We provided evidence that EGR2 deficiency led to impaired zymosan internalization and reduced the capacity to respond to Aspergillus fumigatus. Mechanistically, the lack of EGR2 altered the transcriptional response, secreted cytokines (i.e., CXCL11), and inflammation-resolving lipid mediators (i.e., RvE1) of AMs during in vivo zymosan-induced inflammation, which manifested in impaired resolution. Our findings demonstrated that EGR2 is a key proximal transcriptional activator and epigenomic bookmark in AMs responsible for select, distinct components of cell identity and a protective transcriptional and epigenomic program against fungi.

Indexed as

Aspergillus fumigatusEarly Growth Response Protein 2Macrophages, AlveolarPhagocytosisAnimalsEpigenesis, GeneticEpigenomicsMiceMice, Inbred C57BLMice, KnockoutZymosanEarly Growth Response Protein 2Egr2 protein, mouseZymosanFungal infectionsInfectious diseaseInflammationInnate immunityTranscription

Identifiers

PMID39042472
PMCPMC11385099

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.